New York, USA – July 6, 2021 – Due to the COVID-19 pandemic and the accelerated global vaccination of related vaccines, the demand for nucleoside chemicals is increasing sharply. Pseudouridine and its derivatives, as the most abundant modified form of ribonucleic acid (RNA), play a positive role in maintaining the stability and biological effectiveness of the COVID-19 mRNA vaccine.
Pseudouridine is linked by carbon-carbon rather than nitrogen-carbon glycosidic bonds, which is more biochemically stable and gives the active ingredient a longer biological half-life. In addition, its C-C bond gives pseudouridine more rotational freedom and conformational flexibility.
BOC Sciences recently announced that its cGMP manufacturing platform can provide a large amount of high-quality pseudouridine and its derivatives to meet the production needs of COVID-19 mRNA vaccines, and the pseudouridine can also be used for RNA drug development and other biological research.
With the cGMP manufacturing platform, the New York-based company is able to produce pseudouridine and various derivatives. It’s reported that BOC Sciences’s current annual output of pseudouridine is over 500 kg, making it the largest pseudouridine manufacturer in the world. The company have demonstrated that the derivatives it produces can be integrated into RNA and modify RNA. This is particularly relevant to the production of mRNA-based COVID-19 vaccine products, because the incorporation of pseudouridine into mRNA (especially N1-methylpseudouridine (m1Ψ)) can increase its stability and half-life, thereby increasing the effectiveness of therapeutic vaccines.
The COVID-19 mRNA vaccine is a single-stranded 5’capped mRNA containing the genetic information of the pathogen SARS-CoV-2, which can induce cells to produce viral proteins, which are then presented to the immune system to induce immune responses such as humoral neutralizing antibody responses, Th1 type CD4+ and CD8+ cells responses to block virus infection and kill virus-infected cells respectively. In the mRNA vaccine sequence, Uridine is replaced by modified N1-methylpseudouridine (m1ΨTP), which can improve the safety and effectiveness of the mRNA vaccine against COVID-19.
“On the basis of green chemical synthesis, we provide a more effective method that requires fewer reaction steps and non-toxic chemicals. It can quickly meet the global demand for COVID-19 mRNA vaccine production. Whether it is GMP-grade, industrial-grade, or any other professional level, BOC Sciences has the capability to fulfill any request on chemicals at any scale.” said the Chief Scientist of BOC Sciences.
For more information about pseudouridine, please visit the website: https://www.bocsci.com/pseudouridine-and-its-derivatives.html.
About BOC Sciences
BOC Sciences has been providing high-quality pseudouridine and its derivatives for the production of COVID-19 mRNA vaccines. In the past two decades, BOC Sciences has won the reputation and valuable trust of global customers in the supply of nucleosides/nucleotides, pseudouridines, and other chemicals. Relying on the GMP synthesis platform and rich experience in the development and synthesis of biochemical raw materials, BOC Science also provides drug R&D services covering all stages to support the pharmaceutical industry.